Epcoritamab

From WikiMD.org
Jump to navigation Jump to search

Epcoritamab

Epcoritamab (pronunciation: ep-co-ri-ta-mab) is a bispecific antibody designed for the treatment of B-cell malignancies. It is currently under investigation in clinical trials.

Etymology

The name "Epcoritamab" follows the World Health Organization's guidelines for the naming of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-rit-" suggests that it targets the immune system.

Mechanism of Action

Epcoritamab works by binding to two different proteins: CD3 on T-cells and CD20 on B-cells. This dual binding allows T-cells to directly kill the B-cells, which are often cancerous in B-cell malignancies.

Clinical Trials

Epcoritamab is currently being tested in several clinical trials for its effectiveness against various B-cell malignancies, including Non-Hodgkin lymphoma and Chronic lymphocytic leukemia.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski